PicoCELA (NASDAQ:PCLA) Shares Down 2.1% – Should You Sell?

PicoCELA Inc. (NASDAQ:PCLA)’s share price traded down 2.1% during trading on Thursday . The company traded as low as $6.80 and last traded at $7.04. 60,630 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 950,426 shares. The stock had previously closed at $7.19.

Analysts Set New Price Targets

PCLA has been the subject of several analyst reports. Weiss Ratings raised shares of PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Wall Street Zen raised shares of PicoCELA to a “hold” rating in a research note on Saturday, July 25th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

PicoCELA Price Performance

The firm’s 50-day moving average is $6.46 and its 200-day moving average is $4.68.

PicoCELA (NASDAQ:PCLA) last released its quarterly earnings results on Friday, September 18th. The company reported ($3.30) earnings per share for the quarter. The business had revenue of $1.16 million during the quarter.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.